Can you afford to wait for your cancer diagnosis when your cancer won't wait for you?
Through our Nanogene Solution assays, we offer a state-of-the-art, FDA-cleared for clinical testing, genetic solution that guarantees peace of mind and prompt answers to your inquiries. Recognizing the significance of time, we take pride in being the first laboratory in the UAE to acquire the GENEXUS instrument, allowing us to deliver same-day results for multigene panels, and eliminating the delays caused by sample batching and library preparation. We are committed to delivering results within 1-3 days of sample collection, making us the sole laboratory in the region to promise such efficiency.
We offer
Heme-Oncology Genomic Profiling
Nanogen-Myeloid Profile
Myeloid diseases present a genetically complex group of disorders, and the current standard of care involves routine examining targeted driver mutations to establish or confirm the diagnosis. Our myeloid panel is extensively researched and approved for diagnosing all myeloid disorders, detecting Single Nucleotide Variants (SNVs), Insertions and Deletions, Tandem Duplications, and Gene Fusions.
Disorders covered include: AML, CML, CMML, JMML, MDS, and MPN.
Specimen types:
- Peripheral blood and Bone Marrow
- Cell suspension / flow cytometry sample in RPMI
- Specimen requirements: 20 ng of DNA input
Specimen lower limit of detection: 5% (Assay is not designed to detect mutation burden less than 5%) – assay has 96-97% yield value. Repeat testing on bone marrow samples can help detect early disease with low allele burden in peripheral blood.
| DNA Panel: Full Genes (17) | ANKRD26 | ASXL1 | ABL1 | BAALC | EIF2B1 |
|---|---|---|---|---|
| ABL1 | BCOR | ABL2 | MECOM | FBXW2 |
| BRAF | CALR | BCL2 | MYC | PSMB2 |
| CBL | CEBPA | BRAF | SMC1A | PUM1 |
| CSF3R | ETV6 | CCND1 | WT1 | TRIM27 |
| DDX41 | EZH2 | CREBBP | - | - |
| DNMT3A | IKZF1 | EGFR | - | - |
| FLT3(ITD, | NF1 | ETV6 | - | - |
| TKD) | PHF6 | FGFR1 | - | - |
| GATA2 | PRPF8 | FGFR2 | - | - |
| HRAS | RB1 | FUS | - | - |
| IDH1 | RUNX1 | HMGA2 | - | - |
| IDH2 | SH2B3 | JAK2 | - | - |
| JAK2 | STAG2 | KAT6A (MOZ) | - | - |
| KIT | TET2 | KAT6B | - | - |
| KRAS | TP53 | KMT2A | - | - |
| MPL | ZRSR2 | KMT2A PTDs | - | - |
| MYD88 | - | MECOM | - | - |
| NPM1 | - | MET | - | - |
| NRAS | - | MLLT10 | - | - |
| PPM1D | - | MRTFA (MKL1) | - | - |
| PTPN11 | - | MYBL1 | - | - |
| SMC1A | - | MYH11 | - | - |
| SMC3 | - | NTRK2 | - | - |
| SETBP1 | - | NTRK3 | - | - |
| SF3B1 | - | NUP98 | - | - |
| SRSF2 | - | NUP214 | - | - |
| U2AF1 | - | PAX5 | - | - |
| WT1 | - | PDGFRA | - | - |
| - | - | PDGFRB | - | - |
| - | - | RARA | - | - |
| - | - | RUNX1 | - | - |
| - | - | TCF3 | - | - |
| - | - | TFE3 | - | - |
| - | - | ZNF384 | - | - |
Nanogene-Lymphoid Assay
This panel aims to further classify Diffuse Large B-cell lymphoma, Hodgkin Lymphomas and other low-grade lymphomas.The Nanogene Lymphoma Panel includes 25 gene.
ARID1A
ATM
B2M
BCL2
BCL6
BRAF
BTK
CARD11
CD79B
CDKN2A
CREBBP
EZH2
GNA13
HIST1H1E
KMT2D
MTOR
MYC
MYD88
PIM1
SF3B1
SOCS1
TNFAIP3
TNFRSF14
TP53
XPO1
This panel comprises 976 amplicons
Sample type :
Fine needle aspirate (FNA) samples.
FFPE samples (≥5 unstained slides and one H&E slide), especially small biopsies with low-DNA and questionable lymphoma vs reactive diagnosis.
Assay Design
Record MYC amplification, our report will include copy numbers.
Detect BCL2 and BCL6 translocations, deletions, and gene amplifications.
Identify BRAF mutations to confirm a diagnosis of Hairy cell leukemia.
Identify MYD88 mutations to differentiate between Lymphoplasmacytic lymphoma and other types of low-grade B-cell lymphoma.
Prognostic information in CLL.
Please specify the type of lymphoma to be able to guide your prognostic report information.
Nano-Solid Tumor Assay:
Provide mutations, copy number variations (CNVs), and fusion variants across 50 key genes of relevant biomarkers, including 78 variants and 45 distinct mutations, with a sample yield of over 95%.
Assay Design:
- Provide all relevant biomarker to test for NSCCLC clinical analysis either from FFPE tissue or liquid biopsy sample.
- Provide necessary genetic testing for most GI (colon, upper GI) and GYN cancers. Provides information on gastric HER2/neu (ERBB2) gene.
Colorectal Cancer (14 Genes)
AKT1, BRAF, EGFR, ERBB2, ERBB4, FGFR2, FGFR3, HRAS, KRAS, MET, MAP2K1, NRAS,
NTRK1, PIK3CA.
Gynecological Cancer (12 Genes)
AKT1, BRAF, AR, EGFR, ERBB2, ESR1, FGFR1, FGFR2, KRAS, MYC, NTRK1, PIK3CA.
Melanoma (12 Genes)
BRAF, CDK4, CTNNB1, GNA11, GNAQ, KIT, MAP2K1, NRAS, NTRK1, PDGFRA, PIK3CA, SMO.
NSCLC (15 genes)
EGFR, KRAS, BRAF, RIT, FGFR1, FGFR2, HRAS, NRAS, MAP2K, ERBB2, MET, RET, ROS1, ALK, NF1.
Sample type:
FNA – cytology sample
FFPE, low DNA volume of 10ng DNA or more (≥5 unstained slides and one H&E slide)
Peripheral blood for cfDNA – Assay validated by the manufacture for peripheral blood detection.
Advantages of Nanogene Solid Tumor Assay:
- Single Day Turnaround Assay time (full result within 1-3 business days)
- Panel has screen open design, where we can view both DNA and RNA panel details, download panel-specific files, and custom gene report.
| DNA Hotspots | CNVs | Inter-genetic fusions | Intra-genetic fusions | ||||||
|---|---|---|---|---|---|---|---|---|---|
| AKT1 | CHEK2 | FGFR3 | KIT | NTRK3 | ALK | FGFR1 | ALK | NTRK1 | AR |
| AKT2 | CTNNB1 | FGFR4 | KRAS | PDGFRA | AR | FGFR2 | BRAF | NTRK2 | EGFR |
| AKT3 | EGFR | FLT3 | MAP2K1 | PIK3CA | CD274 | FGFR3 | ESR1 | NTRK3 | MET |
| ALK | ERBB2 | GNA11 | MAP2K2 | PTEN | CDKN2A | KRAS | FGFR1 | NUTM1 | - |
| AR | ERBB3 | GNAQ | MET | RAF1 | EGFR | MET | FGFR2 | RET | - |
| ARAF | ERBB4 | GNAS | MTOR | RET | ERBB2 | PIK3CA | FGFR3 | ROS1 | - |
| BRAF | ESR1 | HRAS | NRAS | ROS1 | ERBB3 | PTEN | MET | RSPO2 | - |
| CDK4 | FGFR1 | IDH1 | NTRK1 | SMO | - | - | NRG1 | RSPO3 | - |
| CDKN2A | FGFR2 | IDH2 | NTRK2 | TP53 | - | - | - | - | - |
Nanogene Solid Tumor (large panel) 500 gene Assay: Coming Soon!
YOUR PATHWAY TO EARLY DIAGNOSIS
Every day, we help healthcare providers treat patients through early detection testing. From specialty diagnostics to cutting-edge science in oncology, chronic diseases, and more, we never stop delivering innovative resources.